PreLabs/BSR offers a broad range of toxicology and preclinical services with expanded capacity supported by a scientific staff providing extensive multi-species expertise.

Oak Park, IL, October 1, 2008 - Biologic Safety Research Inc. (BSR) announced today it is joining PreLabs, LLC to expand its operations. The existing BSR management team will integrate into the PreLabs organization and continue to actively guide the future of the expanded contract laboratory. Additionally, PreLabs has appointed Boris Predovich to serve as President/CEO and Philippe Baneux DVM as Chief Scientific Officer for the newly expanded company.

Biologic Safety Research has been providing toxicology and preclinical services since 1988. "Market demand has created an exciting opportunity for us to expand our business." said Robert Locke, BSR President. "Transitioning BSR into PreLabs will leverage our existing scientific and operational expertise while adding the CRO and pharmaceutical management expertise that Boris Predovich and Philippe Baneux bring with their 20 plus years at Covance and Pfizer respectively."

PreLabs/BSR provides discovery, preclinical and GLP testing in our state-of-the-art, AAALAC International-accredited vivaria. "We will continue the long-established tradition of understanding our clients' requirements and bringing academic and industry leaders together to collaborate and develop innovative strategies that facilitate globally competitive, value-driven outsourcing solutions." said Boris Predovich, PreLabs President/CEO.

For more information please contact us at 1.708.613.6000 or visit www.PreLabs.com.

PreLabs/BSR offers a broad range of toxicology and preclinical services with expanded capacity supported by a scientific staff providing extensive multi-species expertise.

Oak Park, IL, October 1, 2008 - Biologic Safety Research Inc. (BSR) announced today it is joining PreLabs, LLC to expand its operations. The existing BSR management team will integrate into the PreLabs organization and continue to actively guide the future of the expanded contract laboratory. Additionally, PreLabs has appointed Boris Predovich to serve as President/CEO and Philippe Baneux DVM as Chief Scientific Officer for the newly expanded company.

Biologic Safety Research has been providing toxicology and preclinical services since 1988. "Market demand has created an exciting opportunity for us to expand our business." said Robert Locke, BSR President. "Transitioning BSR into PreLabs will leverage our existing scientific and operational expertise while adding the CRO and pharmaceutical management expertise that Boris Predovich and Philippe Baneux bring with their 20 plus years at Covance and Pfizer respectively."

PreLabs/BSR provides discovery, preclinical and GLP testing in our state-of-the-art, AAALAC International-accredited vivaria. "We will continue the long-established tradition of understanding our clients' requirements and bringing academic and industry leaders together to collaborate and develop innovative strategies that facilitate globally competitive, value-driven outsourcing solutions." said Boris Predovich, PreLabs President/CEO.

For more information please contact us at 1.708.613.6000 or visit www.PreLabs.com.

PreLabs offers a broad range of toxicology and preclinical services with expanded capacity supported by a scientific staff providing timely and cost-effective outsourcing solutions.

Oak Park, IL, May 26, 2009 - PreLabs, LLC, a Chicago-based contract research organization, is pleased to announce the addition of Stuart Knight as the Global Director of Business Development. In the newly created position, Stuart will lead the company's business development opportunities by expanding and developing strategic client relationships. His industry experience positions him to understand client requirements and effectively collaborate with the global Pharmaceutical, Biotechnology, Medical Device, Consumer Products and Chemical industries as well as governmental and academic institutions.

Stuart has 20 years of successful international sales and marketing experience. In his most recent role as a senior sales executive with Southern Research Institute he directed sales expansion through a broad spectrum of IND enabling preclinical drug and medical device development and outsourcing services.

He has worked for various organizations including Microbiotest, Inc. where he led the sales and marketing effort in executing strategic business development initiatives focused on accelerated growth and increased market share. During his tenure with the Yamazaki Group he developed a successful international licensing and product distribution program.

"Stuart's collaborative approach to client requirements supports PreLabs' commitment to accurate and timely preclinical outsourcing solutions." said Boris Predovich, PreLabs President & CEO. PreLabs provides contract development services focused on discovery, preclinical and GLP testing in state-of-the-art, AAALAC International-accredited vivaria.

For more information please contact us at 1.708.613.6000 or visit www.PreLabs.com.

PreLabs offers a broad range of toxicology and preclinical services with expanded capacity supported by a scientific staff providing timely and cost-effective outsourcing solutions.

Oak Park, IL, May 26, 2009 - PreLabs, LLC, a Chicago-based contract research organization, is pleased to announce the addition of Stuart Knight as the Global Director of Business Development. In the newly created position, Stuart will lead the company's business development opportunities by expanding and developing strategic client relationships. His industry experience positions him to understand client requirements and effectively collaborate with the global Pharmaceutical, Biotechnology, Medical Device, Consumer Products and Chemical industries as well as governmental and academic institutions.

Stuart has 20 years of successful international sales and marketing experience. In his most recent role as a senior sales executive with Southern Research Institute he directed sales expansion through a broad spectrum of IND enabling preclinical drug and medical device development and outsourcing services.

He has worked for various organizations including Microbiotest, Inc. where he led the sales and marketing effort in executing strategic business development initiatives focused on accelerated growth and increased market share. During his tenure with the Yamazaki Group he developed a successful international licensing and product distribution program.

"Stuart's collaborative approach to client requirements supports PreLabs' commitment to accurate and timely preclinical outsourcing solutions." said Boris Predovich, PreLabs President & CEO. PreLabs provides contract development services focused on discovery, preclinical and GLP testing in state-of-the-art, AAALAC International-accredited vivaria.

For more information please contact us at 1.708.613.6000 or visit www.PreLabs.com.

Oak Park, IL, August 19, 2009 - PreLabs, LLC, a Chicago-based contract research organization, is pleased to announce the addition of Ken Draper, PhD, DABT, as Scientific Consultant.

Dr. Draper has 25 years of experience in discovery and development of small molecule and biotechnology products. During his recent tenure at Charles River Laboratories and Sierra Biomedical, Inc., he amassed substantial experience in understanding the biology of nonhuman primates and their use for toxicology/safety assessments. His drug development expertise encompasses therapeutic modalities/biologics including monoclonal antibodies, vaccines, proteins/peptides, oligonucleotides (including siRNA), and various gene and cell therapy platforms. He has designed and/or managed 50 preclinical programs and has directed 300 toxicology studies in a variety of animal models.

"Ken's expertise and background in virology and molecular genetics along with his extensive industry knowledge advances PreLabs' ability to serve its clients with enhanced efficiency", said Philippe Baneux, PreLabs Chief Scientific Officer.

PreLabs provides contract outsourcing services focused on discovery, preclinical and GLP-compliant testing in state-of-the-art, AAALAC International-accredited vivaria.

For more information please contact us at 1.708.613.6000 or visit www.PreLabs.com.

Oak Park, IL, August 19, 2009 - PreLabs, LLC, a Chicago-based contract research organization, is pleased to announce the addition of Ken Draper, PhD, DABT, as Scientific Consultant.

Dr. Draper has 25 years of experience in discovery and development of small molecule and biotechnology products. During his recent tenure at Charles River Laboratories and Sierra Biomedical, Inc., he amassed substantial experience in understanding the biology of nonhuman primates and their use for toxicology/safety assessments. His drug development expertise encompasses therapeutic modalities/biologics including monoclonal antibodies, vaccines, proteins/peptides, oligonucleotides (including siRNA), and various gene and cell therapy platforms. He has designed and/or managed 50 preclinical programs and has directed 300 toxicology studies in a variety of animal models.

"Ken's expertise and background in virology and molecular genetics along with his extensive industry knowledge advances PreLabs' ability to serve its clients with enhanced efficiency", said Philippe Baneux, PreLabs Chief Scientific Officer.

PreLabs provides contract outsourcing services focused on discovery, preclinical and GLP-compliant testing in state-of-the-art, AAALAC International-accredited vivaria.

For more information please contact us at 1.708.613.6000 or visit www.PreLabs.com.